Literature DB >> 7490805

Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?

C Maulard-Durdux1, B Dufour, C Hennequin, Y Chrétien, B Vignes, D Droz, S Delanian, M Housset.   

Abstract

PURPOSE: To evaluate the role of adjuvant radiation therapy in invasive transitional cell carcinoma of the upper urinary tract, we retrospectively reviewed a series of 26 patients who underwent radical surgery plus postoperative prophylactic irradiation for such a tumor.
MATERIALS AND METHODS: Between February 1980 and October 1993, 18 men and 8 women (mean age 65 +/- 9 years, standard deviation) were treated for an invasive transitional cell carcinoma of the upper urinary tract. Tumor location was the renal pelvis in 15 patients (58%). The tumor was pathological stage B in 11 patients (42%) and stage C in 15 (58%). Tumor grade was 2 in 10 patients, 3 in 15 and unknown in 1. One patient had epidermoid metaplasia of urothelial cancer and 9 had node involvement. All patients underwent surgery followed by radiation therapy to a total dose of 45 Gy. to the tumor bed (23) and/or regional nodes (18).
RESULTS: After a mean followup of 45 months 13 patients (50%) were alive and 11 were disease-free at analysis. Local tumor relapse, nodal recurrence and metastasis were noted in 1, 4 (15%) and 14 (54%) patients, respectively. All patients with nodal recurrence had metastasis. A secondary location was noted frequently (6 bladder, 1 contralateral renal pelvis and 1 urethral tumors). Overall 5-year survival rate and 5-year survival rate with no evidence of disease were 49% and 30%, respectively. Overall 5-year survival rates were 60% for stage B and 19% for stage C disease (p = 0.07), 49% for node-negative versus 15% for node-positive cancer (p = 0.04), and 90% for grade 2 and 0% for grade 3 tumors (p < 0.01).
CONCLUSIONS: In our trial using a radio-surgical approach, local control of disease and survival rates were similar to those reported previously in surgical series. Prophylactic postoperative radiation therapy is not recommended except in prospective randomized studies.

Entities:  

Mesh:

Year:  1996        PMID: 7490805

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Treatment of upper tract urothelial carcinoma: a review of surgical and adjuvant therapy.

Authors:  Kalyan C Latchamsetty; Christopher R Porter
Journal:  Rev Urol       Date:  2006

2.  Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract.

Authors:  C-F Wu; K-F Ng; C-S Chen; P-L Chang; C-K Chuang; W-H Weng; S-K Liao; S-T Pang
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

3.  Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse.

Authors:  Bing Chen; Zhao-Chong Zeng; Guo-Min Wang; Li Zhang; Zong-Ming Lin; Li-An Sun; Tong-Yu Zhu; Li-Li Wu; Jian-Ying Zhang; Yuan Ji
Journal:  BMC Cancer       Date:  2011-07-14       Impact factor: 4.430

4.  Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma.

Authors:  Yun-Ching Huang; Ying-Hsu Chang; Kuo-Hsiung Chiu; Alan W Shindel; Chia-Hsuan Lai
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

5.  Comprehensive management of upper tract urothelial carcinoma.

Authors:  Georgios Koukourakis; Georgios Zacharias; Michael Koukourakis; Kiriaki Pistevou-Gobaki; Christos Papaloukas; Athanasios Kostakopoulos; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2008-12-10

6.  Prognostic factors and outcomes of primary transitional cell carcinoma of the ureter: a population-based study.

Authors:  Tao Ding; Zhuojun Zheng; Renfang Xu; Cuixing Zhou
Journal:  Oncotarget       Date:  2017-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.